CN106032378B - New A RB compound and application thereof - Google Patents
New A RB compound and application thereof Download PDFInfo
- Publication number
- CN106032378B CN106032378B CN201510124540.5A CN201510124540A CN106032378B CN 106032378 B CN106032378 B CN 106032378B CN 201510124540 A CN201510124540 A CN 201510124540A CN 106032378 B CN106032378 B CN 106032378B
- Authority
- CN
- China
- Prior art keywords
- base
- methyl
- carboxylic acid
- oxo
- oxadiazoles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 44
- 206010020772 Hypertension Diseases 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 10
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 claims description 98
- 239000004305 biphenyl Substances 0.000 claims description 73
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 67
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 62
- 150000004702 methyl esters Chemical class 0.000 claims description 59
- 229910052760 oxygen Inorganic materials 0.000 claims description 58
- 239000001301 oxygen Substances 0.000 claims description 56
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 43
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 43
- 239000001257 hydrogen Substances 0.000 claims description 41
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 37
- 235000010290 biphenyl Nutrition 0.000 claims description 34
- WBILDQZWYMFRNR-UHFFFAOYSA-N 3-methyl-1,2,5-oxadiazole Chemical class CC=1C=NON=1 WBILDQZWYMFRNR-UHFFFAOYSA-N 0.000 claims description 30
- IAEGWXHKWJGQAZ-UHFFFAOYSA-N trimethylpyrazine Chemical compound CC1=CN=C(C)C(C)=N1 IAEGWXHKWJGQAZ-UHFFFAOYSA-N 0.000 claims description 29
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 125000004494 ethyl ester group Chemical group 0.000 claims description 21
- NKWCGTOZTHZDHB-UHFFFAOYSA-N 1h-imidazol-1-ium-4-carboxylate Chemical compound OC(=O)C1=CNC=N1 NKWCGTOZTHZDHB-UHFFFAOYSA-N 0.000 claims description 18
- -1 itrile group Chemical group 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 239000007919 dispersible tablet Substances 0.000 claims description 4
- 208000002249 Diabetes Complications Diseases 0.000 claims description 3
- 206010012655 Diabetic complications Diseases 0.000 claims description 3
- 229910002651 NO3 Inorganic materials 0.000 claims description 3
- 239000003405 delayed action preparation Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical class CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 abstract description 14
- 230000036772 blood pressure Effects 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 206010019280 Heart failures Diseases 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 4
- 208000006029 Cardiomegaly Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000001681 protective effect Effects 0.000 abstract description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract description 2
- 206010061216 Infarction Diseases 0.000 abstract description 2
- 230000000747 cardiac effect Effects 0.000 abstract description 2
- 230000004087 circulation Effects 0.000 abstract description 2
- 230000007574 infarction Effects 0.000 abstract description 2
- 239000003112 inhibitor Substances 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 239000002840 nitric oxide donor Chemical class 0.000 abstract description 2
- 230000009885 systemic effect Effects 0.000 abstract description 2
- 208000019622 heart disease Diseases 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 58
- 238000005481 NMR spectroscopy Methods 0.000 description 34
- 230000015572 biosynthetic process Effects 0.000 description 34
- 239000002994 raw material Substances 0.000 description 34
- 238000003786 synthesis reaction Methods 0.000 description 34
- 238000010189 synthetic method Methods 0.000 description 31
- 238000005160 1H NMR spectroscopy Methods 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- PCJFEVUKVKQSSL-UHFFFAOYSA-N 2h-1,2,4-oxadiazol-5-one Chemical class O=C1N=CNO1 PCJFEVUKVKQSSL-UHFFFAOYSA-N 0.000 description 21
- 241000700159 Rattus Species 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000012790 confirmation Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 150000002460 imidazoles Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000001631 hypertensive effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- KXIYCFCVBMFSEH-UHFFFAOYSA-N 2-benzyl-1h-imidazole-5-carboxylic acid Chemical compound OC(=O)C1=CNC(CC=2C=CC=CC=2)=N1 KXIYCFCVBMFSEH-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000012805 post-processing Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229960001866 silicon dioxide Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 230000001077 hypotensive effect Effects 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 4
- OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 description 3
- 239000002083 C09CA01 - Losartan Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 229920003081 Povidone K 30 Polymers 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 229960004773 losartan Drugs 0.000 description 3
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- LAXOCXPBJXIBHO-UHFFFAOYSA-N (3,5,6-trimethylpyrazin-2-yl)methanol Chemical compound CC1=NC(C)=C(CO)N=C1C LAXOCXPBJXIBHO-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000005480 Olmesartan Substances 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 2
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 125000001118 alkylidene group Chemical group 0.000 description 2
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 239000000823 artificial membrane Substances 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960004349 candesartan cilexetil Drugs 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- MLXKRQZNBPENEJ-UHFFFAOYSA-N chloromethyl hydrogen carbonate Chemical compound OC(=O)OCCl MLXKRQZNBPENEJ-UHFFFAOYSA-N 0.000 description 2
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 2
- 229960004563 eprosartan Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229960002198 irbesartan Drugs 0.000 description 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 description 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 2
- 229960005117 olmesartan Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229960005187 telmisartan Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960004699 valsartan Drugs 0.000 description 2
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- WCASXYBKJHWFMY-NSCUHMNNSA-N 2-Buten-1-ol Chemical compound C\C=C\CO WCASXYBKJHWFMY-NSCUHMNNSA-N 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005485 Azilsartan Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- 206010009126 Chronic respiratory failure Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000963390 Curcuma wenyujin Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- DXRFZHILMCWCNG-UHFFFAOYSA-N N,N-dimethyl-1,8-naphthyridin-2-amine Chemical compound C1=CC=NC2=NC(N(C)C)=CC=C21 DXRFZHILMCWCNG-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 description 1
- 229960002731 azilsartan Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BFOMKONSJIIQKV-UHFFFAOYSA-N benzene;2h-tetrazole Chemical compound C1=NN=NN1.C1=CC=CC=C1 BFOMKONSJIIQKV-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- WCASXYBKJHWFMY-UHFFFAOYSA-N gamma-methylallyl alcohol Natural products CC=CCO WCASXYBKJHWFMY-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000002455 vasospastic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention belongs to field of pharmaceutical chemistry technology, specifically disclose a kind of novel hypertension II acceptor inhibitor and its medical usage with good pharmaceutical activity.This kind of compound includes ligustrazine and NO donor analog derivative; ligustrazine or NO can be discharged rapidly out into the human body; both blood pressure lowering curative effect can be played; there is a degree of protective effect to liver kidney again, this kind of drug is suitable for prevention or treatment circulation systemic disease such as hypertension or heart disease such as cardiac hypertrophy, heart failure, cardiac infarction etc..
Description
Technical field
The present invention relates to medical compounds research and development technology fields, and in particular to a kind of new A RB compound and application thereof, it should
New A RB compound is the novel hypertension II acceptor inhibitor with good pharmaceutical activity。
Background technique
AngiotensinⅡ (Ang II) is the important regulating and controlling factor that body fluid dynamic equilibrium is adjusted in body, be related to blood pressure,
Electrolyte balance etc., lot of documents confirm, Ang II high blood pressure, arterial disease, cardiomegaly, heart failure and diabetes,
Main effect is all played in the pathogenesis of nephrosis etc..Since the horizontal aberrant continuation of Ang II increases and hypertension, heart fertilizer
The occurrence and development of thickness, heart failure etc. are directly related, therefore,It blocks Ang II in conjunction with the receptor of its specificity, heart and brain can be played
The protective effect of blood vessel, Angiotensin Ⅱ receptor antagonist (Angiotensin Receptor Blockers, ARB) are dropping
It is confirmed in many randomized clinical trials in terms of low cardiovascular death rate and the benefit of disability rate, ARB drug
In the external wide prevention and treatment for high blood pressure and other cardiorenal diseases, the ARB of clinical use can divide according to structure at present
For 2 classes: (1) Biphenyltetrazoles, including Losartan (losartan), Valsartan (valsartan), Irbesartan
(irbesartan), candesartan Cilexetil (candesartan cilexetil) and Losartan (tasosartan) etc..(2) non-
Benzene tetrazole, including Eprosartan (eprosartan) and Telmisartan (telmisartan).
Nitric oxide has extremely important physiological function, packet as messenger substances and effector molecule in the mammalian body
Control antiotasis, nerve conduction, hormone secretion, inflammation and immune response etc. are included, furthermore to adjusting arterial dilation, cell
Be adhered to blood vessel endothelium and platelet aggregation, vascular smooth muscle cell proliferation and protection ischemical reperfusion injury etc. also have it is important
Effect.
Ligustrazine (Ligustrazine, Lig) is umbelliferae Rhizoma Chuanxiong and zingiberaceous plant Curcuma wenyujin rhizome and Euphorbiaceae
One of main chemical compositions in plant ventilation manioca stem.Pharmacological research proves that ligustrazine has improvement microcirculation, expansion blood
Pipe increases artery blood flow, inhibits the effects of platelet aggregation and reduction biologically active pdgf, has significant curative effect to cardiovascular disease.
Clinically it is widely used in the diseases such as cerebral apoplexy, asthma, pulmonary emphysema, pulmonary heart disease, chronic respiratory failure, adult respiratory distress syndrome (ARDS)
Treatment.
Ligustrazine or NO donor chemical structure are coupled on ARB compound by the applicant, form a kind of new A RB chemical combination
Object, such compound not only has II receptor active of antagonizing angiotensin compared with compound known in the art, but also has to liver kidney
There is a degree of protective effect.
Summary of the invention
For the deficiencies in the prior art, the present invention carries out structural modification to the ARB compound clinically used, repairs
Compound after decorations can discharge rapidly out ligustrazine or NO in vivo, to occur effectively rush to be cooperateed with to inhale with former ARB compound
Adduction not only increases anti-hypertension curative effect, also has certain preventive and therapeutic effect to dyslipidemia and diabetic complication.
A kind of ARB compound provided by the invention, general formula are as follows: Ar-CH2-X
Wherein, X is represented
Wherein, L is singly-bound or-O-；R0It is C1-6Alkyl replaces alkyl or 3 to 6 yuan of naphthenic base；
R1aRepresentative-CH2OC (=O) OR1aa、-CH(C1-4Alkyl) OC (=O) OR1aa、
Wherein, R1aaIt represents
Wherein, R6Represent phenyl, substituted-phenyl, heteroaromatic, replace heteroaromatic, benzenesulfonyl, itrile group, trifluoromethyl ,-
C1-4Alkylene nitrate or-C1-4Alkyl；
Wherein, R2And R3It is identical or different, and respectively represent hydrogen, C1-6Alkyl or phenyl；
Wherein, Y1It is C2-7 alkylidenes or Y1For by alkyl, hydroxyl, carboxyl, amido, guanidine radicals ,-C3-6Naphthenic base or phenyl
Substituted alkylidene, or be-(CH2)p-(CY3R4)q-(CH2) r-, wherein when p is 0 or 1, r is 0 or 1, q 1；When p is
When 2-8, q and r are respectively 0；
Wherein, R4Represent hydrogen or C1-6Alkyl；
Y2For C=O, O=S=O or-O-C (=O)-, wherein the carbon atom for being connected with carbonyl in-O-C (=O)-is connected toIn nitrogen-atoms；
Y3It is C1-4 alkyl, phenyl, or by hydroxyl, C1-4Alkyl, C3-6The C that naphthenic base, phenyl, imidazole radicals replace1-4Alkane
Base, or the phenyl replaced by hydroxyl, 3 to 6 yuan of naphthenic base, phenyl, imidazole radicals；
Ar is selected from following aryl:
Wherein, R1For-COORa、-SO2NHR1c、-SO2OH、-O-CH(R2)-COOH, tetrazole radical -5- base,
Wherein, RaRepresent hydrogen, morpholine ,-C1-6Alkyl ,-C1-3Alkylene aryl ,-C1-3Alkylene heteroaryl ,-C3-6Cycloalkanes
Base ,-CH (C1-4Alkyl) OC (=O) R1b、-C1-6Alkylene morpholine ,-CH2OC (=O) OR1b、-CH(C1-6 alkyl) OC (=O)
OR1b、-CH(C1-6 alkoxies) OC (=O) OR1b or
Wherein, R1bIt is C1-4 alkyl replace alkyl, phenyl, substituted-phenyl, heteroaromatic, virtue substituted on carbon atom
Heterocycle, itrile group, trifluoromethyl, C1-6Alkoxy ,-C1-6Alkylene nitrate, C1-6Alkyl, C2-6Alkylene, C2-6Alkynes base ,-O-
C1-6Alkyl, C3-6Naphthenic base, NR1abR1acOr-CH (NH2)CH2COOCH3；
Wherein R1abAnd R1acRespectively represent hydrogen, C1-6Alkyl or benzyl or R1abR1acFor C3-6Naphthenic base；
R1cRepresent hydrogen, aryl ,-C1-6Alkyl, C2-6Alkylene-OH, C0-6Alkylene-O-C1-6Alkyl, C0-6Alkylene-O-
C1-6Alkyl ,-C1-5Alkylene-NR1cdR1cc、-C1-4Alkylene aryl ,-CHO ,-C (=O) C1-6Alkyl ,-C (=O) NH2Or-C
(=O) NH-C1-6Alkyl, wherein R1cdAnd R1ccRespectively represent hydrogen and-C1-6Alkyl, or it is combined into-(CH together2)2-O-(CH2)2-
Or-(CH2)2- N [C (=O) CH3]-(CH2)2-；
The substitution alkyl refers to one or more selected from hydroxyl, C1-6Alkyl, C1-6Alkoxy, halogen, nitro, ammonia
The alkyl that base, itrile group, trifluoromethyl replace, each substituent group may be the same or different；
The substituted-phenyl refers to one or more selected from hydroxyl, C1-6Alkyl, C1-6Alkoxy, halogen, nitro, ammonia
The phenyl that base, itrile group, trifluoromethyl replace, each substituent group may be the same or different；
The heteroaromatic refers to containing 1-4 heteroatomic 5-7 member aromatic rings, the hetero atom be each independently selected from O,
S or N；
The heteroaromatic substituted on carbon atom is optionally to be selected from C by one or more1-6Alkyl, C1-6Alcoxyl
The heteroaromatic of the group substitution of base, halogen, each substituent group may be the same or different.
General formula Ar-CH of the invention2Representative compound is as follows in-X:
QR1009:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic
Sour (phenyl -1,2,5 4-,-oxadiazoles -2- oxo -3- base) methyl esters
QR1017:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic
Sour (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen) methyl esters
QR1019:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic
Sour [1- (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester
QR1020:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic
Sour (3- methyl-1,2,5- oxadiazoles -2- oxo -4- methoxyl group-oxo phosphinylidyne oxygen) methyl esters
QR1021:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic
Sour [1- (3- methyl-1,2,5- oxadiazoles -2- oxide -4- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester
QR1023:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic
Sour (3- methyl-1,2,5- oxadiazoles -2- oxide -4- base) methyl esters
QR1034:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic
Sour (3- nitrate -1,2,5- oxadiazoles -2- oxo -4- base) methyl esters
QR1036:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic
Sour (3- itrile group -1,2,5- oxadiazoles -2- oxo -4- base) methyl esters
QR2009:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] imidazoles -
5- carboxylic acid (phenyl -1,2,5 4-,-oxadiazoles -2- oxo -3-) methyl esters
QR2017:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] imidazoles -
5- carboxylic acid (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen) methyl esters
QR2019:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] imidazoles -
5- carboxylic acid [1- (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester
QR2020:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] imidazoles -
5- carboxylic acid (3- methyl-1,2,5- oxadiazoles -2- oxo -4- methoxyl group-oxo phosphinylidyne oxygen) methyl esters
QR2021:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] imidazoles -
5- carboxylic acid [1- (3- methyl-1,2,5- oxadiazoles -2- oxide -4- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester
QR2034:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] imidazoles -
5- carboxylic acid (3- nitrate -1,2,5- oxadiazoles -2- oxo -4- base) methyl esters
{ [(5- oxo -4,5- dihydro -1,2,4- is disliked 2- 4- QR2109:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1-
Diazole -3)-phenyl] benzyl } imidazole-5-carboxylic acid (phenyl -1,2,5 4-,-oxadiazoles -2- oxo -3-) methyl esters
{ [(5- oxo -4,5- dihydro -1,2,4- is disliked 2- 4- QR2117:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1-
Diazole -3)-phenyl] benzyl } imidazole-5-carboxylic acid (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen) methyl esters
{ [(5- oxo -4,5- dihydro -1,2,4- is disliked 2- 4- QR2119:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1-
Diazole -3)-phenyl] benzyl } imidazole-5-carboxylic acid (phenyl -1,2,5 4-,-oxadiazoles -2- oxo -3-) methyl esters
{ [(5- oxo -4,5- dihydro -1,2,4- is disliked 2- 4- QR2120:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1-
Diazole -3)-phenyl] benzyl } imidazole-5-carboxylic acid (3- methyl-1,2,5- oxadiazoles -2- oxo -4- methoxyl group-oxo phosphinylidyne oxygen)
Methyl esters
{ [(5- oxo -4,5- dihydro -1,2,4- is disliked 2- 4- QR2121:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1-
Diazole -3)-phenyl] benzyl } imidazole-5-carboxylic acid [1- (3- methyl-1,2,5- oxadiazoles -2- oxide -4- methoxyl group-oxo carbon
Acyl-oxygen)] ethyl ester
{ [(5- oxo -4,5- dihydro -1,2,4- is disliked 2- 4- QR2123:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1-
Diazole -3)-phenyl] benzyl } imidazole-5-carboxylic acid (3- methyl-1,2,5- oxadiazoles -2- oxo -4- base) methyl esters
{ [(5- oxo -4,5- dihydro -1,2,4- is disliked 2- 4- QR2136:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1-
Diazole -3)-phenyl] benzyl } imidazole-5-carboxylic acid (3- itrile group -1,2,5- oxadiazoles -2- oxo -4- base) methyl esters
QR3009:N- [1- carboxylic acid (phenyl -1,2,5 4-,-oxadiazoles -2- oxo -3- base) methyl esters -2- methyl-propyl -1-
Base]-N- valeryl-N- [2'- (1H-TETRAZOLE -5- base)-biphenyl -4- base-methyl]-amine
QR3017:N- [1- carboxylic acid (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen) methyl esters -2- methyl-prop
Base -1- base]-N- valeryl-N- [2'- (1H-TETRAZOLE -5- base)-biphenyl -4- base-methyl]-amine
QR3019:N- { 1- carboxylic acid [1- (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester -2- methyl
Propyl -1- base }-N- valeryl-N- [2'- (1H-TETRAZOLE -5- base)-biphenyl -4- base-methyl]-amine
QR3020:N- [1- carboxylic acid (3- methyl-1,2,5- oxadiazoles -2- oxo -4- methoxyl group-oxo phosphinylidyne oxygen) methyl esters -
2- methyl-propyl -1- base]-N- valeryl-N- [2'- (1H-TETRAZOLE -5- base)-biphenyl -4- base-methyl]-amine
QR3021:N- { 1- carboxylic acid [1- (3- methyl-1,2,5- oxadiazoles -2- oxide -4- methoxyl group-oxo phosphinylidyne
Oxygen)] ethyl ester -2- methyl-propyl -1- base }-N- valeryl-N- [2'- (1H-TETRAZOLE -5- base)-biphenyl -4- base-methyl]-amine
QR3034:N- [1- carboxylic acid (3- nitrate -1,2,5- oxadiazoles -2- oxo -4- base) methyl esters -2- methyl-propyl -
1- yl]-N- valeryl-N- [2'- (1H-TETRAZOLE -5- base)-biphenyl -4- base-methyl]-amine
QR3109:N- [1- carboxylic acid (phenyl -1,2,5 4-,-oxadiazoles -2- oxo -3- base) methyl esters -2- methyl-propyl -1-
Base]-N- valeryl-N- [2'- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-methyl]-amine
QR3117:N- [1- carboxylic acid (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen) methyl esters -2- methyl-prop
Base -1- base]-N- valeryl-N- [2'- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-methyl] -
Amine
QR3119:N- { 1- carboxylic acid [1- (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester -2- methyl
Propyl -1- base }-N- valeryl-N- [2'- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-first
Base]-amine
QR3120:N- [1- carboxylic acid (3- methyl-1,2,5- oxadiazoles -2- oxo -4- methoxyl group-oxo phosphinylidyne oxygen) methyl esters -
2- methyl-propyl -1- base]-N- valeryl-N- [2'- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4-
Base-methyl]-amine
QR3121:N- { 1- carboxylic acid [1- (3- methyl-1,2,5- oxadiazoles -2- oxide -4- methoxyl group-oxo phosphinylidyne
Oxygen)] ethyl ester -2- methyl-propyl -1- base }-N- valeryl-N- [2'- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base) -
Biphenyl -4- base-methyl]-amine
QR3123:N- [1- carboxylic acid (3- methyl-1,2,5- oxadiazoles -2- oxo -4- base) methyl esters -2- methyl-propyl -1-
Base]-N- valeryl-N- [2'- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-methyl]-amine
QR3134:N- [1- carboxylic acid (3- nitrate -1,2,5- oxadiazoles -2- oxo -4- base) methyl esters -2- methyl-propyl -
1- yl]-N- valeryl-N- [2'- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-methyl]-amine
The corresponding chemical structural formula of above compound is as follows:
Compound or pharmaceutically acceptable salt thereof provided by the present invention can be used for treating needs selectivity excitement AT2The disease of receptor
Disease.
Pharmaceutical preparation made of the compounds of this invention and its salt can be used for treating hypertension, heart failure, chronic stable
Angina pectoris, vasospastic, apoplexy, myocardial infarction, transient ischemic attack, cardiovascular disease, atherosclerosis,
Diabetes, the disease of insulin resistance, glucose tolerance reduction, pre-diabetes, diabetes B, diabetic nephropathy, metabolism
Syndrome (syndrome X), obesity, dyslipidemia, hypertriglyceridemia, Serum Apoprotein concentration is higher, serum is low
Density lipoprotein-cholesterol concentration is higher, serum lipoprotein associated phospholipase concentration is higher, serum High Density Lipoprotein Cholesterol
Concentration is relatively low, serum hdl (2b) cholesterol concentration is relatively low, serum adiponectin concentration is relatively low.
Another aspect of the present invention provides the pharmaceutical preparation containing the compounds of this invention or its officinal salt, and the preparation can
To be dispersible tablet, Liposomal formulation or sustained release preparation, wherein dispersible tablet includes lactose, microcrystalline cellulose, low substituted hydroxy-propyl fibre
Tie up element, crospovidone, PVP K30, superfine silica gel powder, magnesium stearate and/or aspartame；Liposomal formulation includes phosphatidyl
Choline, cholesterol, NaGC and/or sojasterol；Sustained release preparation includes carbomer and/or Compritol 888 ATO.
Compared with prior art, it is the advantages of technical solution of the present invention with beneficial effect:
New A RB compound provided by the present invention not only has as angiotensin receptor antagonist structure novel
Good hypotensive activity, and bioavilability is high, is suitable for prevention or treatment circulation systemic disease such as hypertension, heart
Sick (cardiac hypertrophy, heart failure, cardiac infarction etc.) and metabolic disease such as diabetic complication and dyslipidemia etc..
Specific embodiment
Applicant will the present invention is described in further detail in conjunction with specific embodiments below, it is therefore intended that so that this
Field technical staff more clearly understands the present invention, but the following contents should not be construed in any way to want the application right
Ask the limitation of the claimed range of book.
Unless otherwise specified, the conventional hand that technological means used in embodiment is well known to the skilled person
Section.
Embodiment 1: the preparation of each compound, such as following (1)-(34) Xiang Suoshu
(1) QR1009:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -
The synthesis of 7- carboxylic acid (phenyl -1,2,5 4-,-oxadiazoles -2- oxo -3- base) methyl esters
10.0g cinnamyl alcohol and 10ml glacial acetic acid are added into 50ml there-necked flask, is cooled to 0 DEG C after stirring and dissolving,It will
15.50g (3eq) sodium nitrite is dissolved in wiring solution-forming in 20g water, and the water-soluble of sodium nitrite is added dropwise between 0 DEG C to 5 DEG C in temperature control
Liquid is added dropwise, and after 0 DEG C of stirring 5min, is warming up to room temperature reaction 12h.Stop reaction, 50ml water, ethyl acetate extraction is added
(40ml*2), merges organic phase, and saturated common salt washing is primary,Anhydrous sodium sulfate is dry, is spin-dried for, obtains 20.0g crude product；Crude product is used
10.0g acidic alumina is added in the dissolution of 40ml acetonitrile, and 60 DEG C are stirred at reflux reaction 3h, and solvent is spin-dried for, solid 100ml acetic acid
Ethyl ester dissolution, filters, and solid is washed (50ml*2) with ethyl acetate, and it is 8- that filtrate, which is washed till pH value with dilute sodium hydroxide (5%-10%),
9, primary (50ml) is extracted with ethyl acetate in liquid separation, water phase again, merges organic phase, saturated common salt washing,Anhydrous sodium sulfate is dry,
It is spin-dried for.Silica gel post separation (petroleum ether: ethyl acetate=7:1-3:1) obtains 2- oxo -3- hydroxymethyl -4- phenyl -1,2,
5 ,-oxadiazoles sterling 5.0g, yield 35.0%.
By 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic acid
(2.2mmol, 1.0 equivalents) and phenyl -1,2,5 2- oxo -3- hydroxymethyl -4-,-oxadiazoles (2.6mmol, 1.2 equivalents) are molten
Solution is cooled to 10 DEG C in 20mL dimethylformamide, is added potassium carbonate (2.6mmol, 1.2 equivalents), paratoluensulfonyl chloride
(2.6mmol, 1.2 equivalents), catalyst dimethylamino naphthyridine,Stir 3h.Water and acetic acid second are added into reaction solution for end of reaction
Ester extraction.Organic layer is successively washed, saturated common salt water washing.Dry concentration crude product obtains target compound through column chromatographic purifying,
Its structure is confirmed through hydrogen nuclear magnetic resonance spectrogram.H-NMR(CDCl3, 400MHz) and δ: 7.88-7.90 (1H, m), 7.76-7.79 (2H,
M), 7.46-7.59 (4H, m), 7.30 (2H, m), 7.08-7.17 (4H, m), 5.63 (2H, s), 5.14 (2H, d), 4.25 (2H,
Q), 1.48 (3H, t).
Compound 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic
Acid can refer to the preparation of method described in CN1055927 patent document.
(2) QR1017:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -
The synthesis of 7- carboxylic acid (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen) methyl esters
Step (1): addition 2- methylol -3,5 in 50ml there-necked flask, 6- trimethylpyrazine (500mg, 3.29mmol),
Methylene chloride (10mL), chloro-methyl-chloroformate (460mg, 3.6mmol), mixed liquor temperature control are added dropwise pyridine (0.32mL) at -2 DEG C
It controls temperature and is no more than 3 DEG C, reaction solution is added dropwise is warming up to and be stirred overnight at room temperature, TLC (petrol ether/ethyl acetate=1:
3) raw material fully reacting, reaction solution filtering are monitored, filtrate is spin-dried for, obtains 1.1g yellow oil, prepare plate and purify to obtain 620mg
3,5,6- trimethylpyrazine -2- methoxyl group carbonic acid chloromethyl ester.
Step (2): 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- is sequentially added in 50mL there-necked flask
Base] methyl } -1H- benzimidazole -7- carboxylic acid (0.77g, 1.69mmol), 3,5,6- trimethylpyrazine -2- methoxyl group carbonic acid chloromethanes
Ester (0.62g, 2.54mmol), N-Methyl pyrrolidone (15mL), triethylamine (0.34g, 3.39mmol).Mixed liquor is at 65 DEG C
Stirring 2 hours, TLC contact plate (methylene chloride:Methanol=10:1), fully reacting.
Post-processing: reaction solution is poured into 75mL water, adds 1N HCl to adjust pH value to 6-7, the white emulsion of solution adds
Methyl tertiary butyl ether(MTBE) extracts (50mL), and saturation NaCl washes (50mL*2) twice, anhydrous Na2SO4It is dry, it is spin-dried for, obtains 1.2g yellow
Liquid, silicagel column obtain 586mg white object compound after purification, and structure is confirmed through hydrogen nuclear magnetic resonance spectrogram.H-NMR
(CDCl3, 400MHz) and δ: 7.87-7.90 (1H, m), 7.76-7.80 (2H, m), 7.51-7.62 (4H, m), 7.30 (2H, m),
7.07-7.15 (3H, m), 5.63 (2H, s), 5.12 (2H, d), 4.23 (2H, q), 2.35 (3H, s), 2.25 (6H, s), 1.49
(3H, t).
(3) QR1019:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -
The synthesis of 7- carboxylic acid [1- (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester
Step 1): addition 2- methylol -3,5 in 50ml there-necked flask, 6- trimethylpyrazine (500mg, 3.29mmol), two
Chloromethanes (10mL), chloro-carbonic acid 1- chloroethene ester (460mg, 3.6mmol), mixed liquor temperature control are added dropwise pyridine (0.32mL) at -2 DEG C
It controls temperature and is no more than 3 DEG C, reaction solution is added dropwise is warming up to and be stirred overnight at room temperature, TLC (petrol ether/ethyl acetate=1:
3) raw material fully reacting, reaction solution filtering are monitored, filtrate is spin-dried for, obtains 1.1g yellow oil, prepare plate and purify to obtain 650mg
3,5,6- trimethylpyrazine -2- methoxyl group carbonic acid 1- chloroethene ester.
Step 2): 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] is sequentially added in 50mL there-necked flask
Methyl } -1H- benzimidazole -7- carboxylic acid (0.77g, 1.69mmol), 3,5,6- trimethylpyrazine -2- methoxyl group carbonic acid 1- chloroethenes
Ester (0.62g, 2.4mmol), N-Methyl pyrrolidone (15mL), triethylamine (0.34g, 3.39mmol).Mixed liquor is at 65 DEG C
Stirring 2 hours, TLC contact plate (methylene chloride: methanol=10:1), fully reacting.
Post-processing: reaction solution is poured into 75mL water, adds 1N HCl to adjust pH value to 6-7, the white emulsion of solution adds
Methyl tertiary butyl ether(MTBE) extracts (50mL), and saturation NaCl washes (50mL*2) twice, anhydrous Na2SO4 is dry, is spin-dried for, and obtains 1.2g Huang
Color liquid, silicagel column obtain 550mg target compound after purification, and structure is confirmed through hydrogen nuclear magnetic resonance spectrogram.H-NMR
(CDCl3, 400MHz) and δ: 7.88-7.90 (1H, m), 7.75-7.78 (2H, m), 7.53-7.61 (4H, m), 7.26 (2H, m),
7.05-7.18 (2H, m), 6.88-6.92 (1H, q), 5.64 (2H, s), 5.14 (2H, d), 4.27 (2H, q), 2.31 (3H, s),
2.23 (6H, s), 1.57-1.60 (3H, d), 1.48 (3H, t).
(4) QR1020:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -
The synthesis of 7- carboxylic acid (3- methyl-1,2,5- oxadiazoles -2- oxo -4- methoxyl group-oxo phosphinylidyne oxygen) methyl esters
For synthetic method with (2) item in embodiment 1, but by raw material 2- methylol -3,5,6- trimethylpyrazine changes 3- into
Methyl -2- oxo -4- methylol -1,2,5- oxadiazoles, chloro-carbonic acid 1- chloroethene ester are changed to chloro-methyl-chloroformate, 3- methyl -2- oxygen
Generation -4- methylol -1,2, described in (1) the item first segment of 5- oxadiazoles during the preparation method is the same as that of Example 1, but starting material is by meat
Cinnamic alcohol changes 2- butenol into；
3- methyl -2- oxo -4- methylol -1,2,5- oxadiazoles and chloro-methyl-chloroformate generate 3- methyl-1, and 2,5- is disliked
Diazole -2- oxo -4- methoxyl group carbonic acid chloromethyl ester, product again with 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4-
Base] methyl } -1H- benzimidazole -7- carboxylic acid reaction obtains target compound, and structure is confirmed through hydrogen nuclear magnetic resonance spectrogram.H-NMR
(CDCl3, 400MHz) and δ: 7.90-7.92 (1H, m), 7.74-7.79 (2H, m), 7.55-7.63 (4H, m), 7.23 (2H, m),
7.04-7.20 (3H, m), 5.61 (2H, s), 5.20 (2H, d), 4.23 (2H, q), 2.35 (3H, s), 1.52 (3H, t).
(5) QR1021:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -
The synthesis of 7- carboxylic acid [1- (3- methyl-1,2,5- oxadiazoles -2- oxide -4- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester
For synthetic method with (3) item in embodiment 1, but by raw material 2- methylol -3,5,6- trimethylpyrazine changes 3- into
Methyl -2- oxo -4- methylol -1,2,5- oxadiazoles, target compound structure are confirmed through hydrogen nuclear magnetic resonance spectrogram.H-NMR
(CDCl3, 400MHz) and δ: 7.89-7.92 (1H, m), 7.73-7.76 (2H, m), 7.57-7.68 (4H, m), 7.24 (2H, m),
7.08-7.14 (2H, m), 6.84-6.89 (1H, q), 5.59 (2H, s), 5.02 (2H, d), 4.27 (2H, q), 2.33 (3H, s),
1.58-1.63 (3H, d), 1.46 (3H, t).
(6) QR1023:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -
The synthesis of 7- carboxylic acid (3- methyl-1,2,5- oxadiazoles -2- oxide -4- base) methyl esters
By 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzene in 100ml single port bottle
And imidazoles -7- carboxylic acid (1.46g, 3.2mmol) is dissolved in 25mL n,N-Dimethylformamide, sequentially adds 2- oxo -3- first
Base -4- methylol -1,2,5,-oxadiazoles (0.5g, 3.85mmol), paratoluensulfonyl chloride (0.73g, 3.85mmol), potassium carbonate
Reaction 3 hours, contact plate (petroleum ether: second is stirred at room temperature in (0.06g) lutidines amine of (0.88g, 6.4mmol) and catalytic amount
Acetoacetic ester=1:3) detection.
Post-processing: being added 50 milliliters of water in reaction solution, ethyl acetate extracts (60ml*3), and organic phase successively uses 100 milliliters
Saturated sodium bicarbonate is washed, 100 milliliters of saturated common salt water washings.Anhydrous sodium sulfate dries, filters,It is spin-dried for, obtains 1.9g yellow oil
Shape liquid, column chromatography for separation (petroleum ether: ethyl acetate=1.5:1-1:2), obtains 800mg white object compound, structure
It is confirmed through hydrogen nuclear magnetic resonance spectrogram.H-NMR(CDCl3, 400MHz) and δ: 7.91-7.93 (1H, m), 7.76-7.82 (2H, m),
7.54-7.61 (4H, m), 7.21 (2H, m), 7.06-7.17 (2H, m), 5.64 (2H, d), 5.13 (2H, d), 4.20 (2H, q),
2.39 (3H, s), 1.50 (3H, t).
(7) QR1034:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -
The synthesis of 7- carboxylic acid (3- nitrate -1,2,5- oxadiazoles -2- oxo -4- base) methyl esters
Step 1): by 3- methyl -2- oxo -4- methylol -1,2,5- oxadiazoles (0.05mol) in 100mL single port bottle
It is dissolved in methylene chloride (50mL), N- bromo-succinimide (0.06mol) and benzoyl peroxide (2.5mM) is added, adds
Heat 5 hours of reflux, TLC detection, raw material disappear；
Post-processing: 50mL saturated sodium bicarbonate solution is added and is quenched；Methylene chloride extracts (60mL*3), 100 milliliters of saturations
Brine It.Anhydrous sodium sulfate dries, filters, and is spin-dried for, and obtains 6.5g yellow oily liquid, and column chromatography for separation obtains 2.0g
2- oxo -3- bromomethyl -4- methylol -1,2,5- oxadiazoles.
Step 2): by 2- oxo -3- bromomethyl -4- methylol -1,2,5- oxadiazoles in 100mL single port bottle
(0.0048mol) is dissolved in acetonitrile (50mL), is added silver nitrate (0.0055mol), and 0.5 hour, TLC inspection are heated to reflux
It surveys, raw material disappears；
Post-processing: 50mL water quenching is added and goes out；Methylene chloride extracts (60mL*3), 100 milliliters of saturated common salt water washings.It is anhydrous
Sodium sulphate dries, filters, and is spin-dried for, and obtains 0.9g yellow oily liquid, column chromatography for separation,Obtain 630mg 2- oxo -3- nitric acid
Methyl -4- methylol -1,2,5- oxadiazoles.
Step 3): 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic
Sour (2.2mmol, 1.0 equivalents) and 2- oxo -3- nitrate -4- methylol -1,2,5- oxadiazoles (2.6mmol, 1.2 equivalents)
It is dissolved in 20mL methylene chloride, N, N'- Dicyclohexylcarbodiimide (4.4mmol, 2.0 equivalents), catalyst diformazan ammonia is added
Yl pyridines.It is stirred overnight at room temperature.Water, methylene chloride extraction are added into reaction solution for end of reaction.Organic layer is successively washed with water,
Saturated common salt water washing.Dry concentration crude product obtains target compound through column chromatographic purifying, and structure is through hydrogen nuclear magnetic resonance spectrogram
Confirmation.H-NMR(CDCl3, 400MHz) and δ: 7.87-7.90 (1H, m), 7.78-7.84 (2H, m), 7.52-7.60 (4H, m),
7.22 (2H, m), 7.04-7.18 (2H, m), 5.66 (2H, d), 5.12 (2H, d), 4.93 (2H, d), 4.22 (2H, q), 1.47
(3H, t).
(8) QR1036:2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -
The synthesis of 7- carboxylic acid (3- itrile group -1,2,5- oxadiazoles -2- oxo -4- base) methyl esters
By 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic acid
(2.2mmol, 1.0 equivalents) and 2- oxo -3- itrile group -4- bromomethyl -1,2,5- oxadiazoles (3.3mmol, 1.5 equivalents) are dissolved in
It in 20mL N-Methyl pyrrolidone, is added triethylamine (4.4mmol, 2.0 equivalents), is heated to 65 DEG C, TLC monitoring reaction is reacted
It finishes.Water and ethyl acetate are added into reaction solution, extracts liquid separation, organic layer is successively washed with water, saturated common salt water washing.It is organic
The dry concentration of layer, column chromatographic purifying obtain target compound, and structure is confirmed through hydrogen nuclear magnetic resonance spectrogram.H-NMR(CDCl3,
400MHz) δ: 7.89-7.93 (1H, m), 7.79-7.83 (2H, m), 7.54-7.62 (4H, m), 7.23 (2H, m), 7.03-7.13
(2H, m), 5.59 (2H, d), 5.16 (2H, d), 4.19 (2H, q), 1.46 (3H, t).
The preparation method of 2- oxo -3- itrile group -4- bromomethyl -1,2,5- oxadiazoles refers to Medicinal Chemistry
Research,11(6),322-332；2002.
(9) QR2009:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] miaow
The synthesis of azoles -5- carboxylic acid (phenyl -1,2,5 4-,-oxadiazoles -2- oxo -3-) methyl esters
Synthetic method is with (1) item in embodiment 1, and preparing raw material, { [2'- (1H-TETRAZOLE -5- base) joins by 2- ethyoxyl -1-
Benzene -4- base] methyl } -1H- benzimidazole -7- carboxylic acid is changed to 4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H-
Tetrazolium -5- phenyl) benzyl] imidazole-5-carboxylic acid, structure confirms through hydrogen nuclear magnetic resonance spectrogram.H-NMR(CDCl3, 400MHz) and δ:
7.87-7.90 (1H, m), 7.61-7.68 (4H, m), 7.34-7.43 (7H, m), 7.08-7.17 (2H, m), 5.48 (2H, d),
5.04 (2H, d), 2.68 (H, t), 2.2 (1H, s), 1.73 (2H, m), 1.62 (6H, d), 1.02 (3H, t).
4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] imidazole-5-carboxylic acid
Synthetic method with reference to method described in CN1045770 patent.
(10) QR2017:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl]
The synthesis of imidazole-5-carboxylic acid (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen) methyl esters
Synthetic method is with (2) item in embodiment 1, and preparing raw material, { [2'- (1H-TETRAZOLE -5- base) joins by 2- ethyoxyl -1-
Benzene -4- base] methyl } -1H- benzimidazole -7- carboxylic acid is changed to 4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H-
Tetrazolium -5- phenyl) benzyl] imidazole-5-carboxylic acid, structure confirms through hydrogen nuclear magnetic resonance spectrogram.H-NMR(CDCl3, 400MHz) and δ:
7.85-7.89 (2H, m), 7.63-7.69 (2H, d), 7.44 (2H, m), 7.10-7.15 (3H, m), 5.53 (2H, d), 5.12
(2H, d), 2.66 (H, t), 2.35 (3H, s), 2.25 (6H, s), 2.0 (1H, s), 1.75 (2H, m), 1.64 (6H, d), 1.04
(3H, t).
(11) QR2019:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl]
The synthesis of imidazole-5-carboxylic acid [1- (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester
Synthetic method is with (3) item in embodiment 1, and preparing raw material, { [2'- (1H-TETRAZOLE -5- base) joins by 2- ethyoxyl -1-
Benzene -4- base] methyl } -1H- benzimidazole -7- carboxylic acid is changed to 4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H-
Tetrazolium -5- phenyl) benzyl] imidazole-5-carboxylic acid, structure confirms through hydrogen nuclear magnetic resonance spectrogram.H-NMR(CDCl3, 400MHz) and δ:
7.83-7.87 (2H, m), 7.66-7.71 (2H, d), 7.46 (2H, m), 7.08-7.14 (3H, m), 6.91-6.95 (1H, q),
5.50 (2H, d), 5.18 (2H, d), 2.62 (H, t), 2.31 (3H, s), 2.22 (6H, s), 2.3 (1H, s), 1.88 (3H, d),
1.77 (2H, m), 1.60 (6H, d), 0.98 (3H, t).
(12) QR2020:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl]
The synthesis of imidazole-5-carboxylic acid (3- methyl-1,2,5- oxadiazoles -2- oxo -4- methoxyl group-oxo phosphinylidyne oxygen) methyl esters
Synthetic method is with (4) item in embodiment 1, and preparing raw material, { [2'- (1H-TETRAZOLE -5- base) joins by 2- ethyoxyl -1-
Benzene -4- base] methyl } -1H- benzimidazole -7- carboxylic acid is changed to 4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H-
Tetrazolium -5- phenyl) benzyl] imidazole-5-carboxylic acid, structure confirms through hydrogen nuclear magnetic resonance spectrogram.H-NMR(CDCl3, 400MHz) and δ:
7.83-7.88 (2H, m), 7.65-7.74 (2H, d), 7.42 (2H, m), 7.12-7.16 (3H, m), 5.54 (2H, d), 5.10
(2H, d), 2.69 (H, t), 2.33 (3H, s), 2.30 (1H, s), 1.71 (2H, m), 1.60 (6H, d), 1.01 (3H, t).
(13) QR2021:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl]
The synthesis of imidazole-5-carboxylic acid [1- (3- methyl-1,2,5- oxadiazoles -2- oxide -4- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester
Synthetic method is with (5) item in embodiment 1, and preparing raw material, { [2'- (1H-TETRAZOLE -5- base) joins by 2- ethyoxyl -1-
Benzene -4- base] methyl } -1H- benzimidazole -7- carboxylic acid is changed to 4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H-
Tetrazolium -5- phenyl) benzyl] imidazole-5-carboxylic acid, structure confirms through hydrogen nuclear magnetic resonance spectrogram.H-NMR(CDCl3, 400MHz) and δ:
7.79-7.85 (2H, m), 7.62-7.68 (2H, d), 7.48 (2H, m), 7.03-7.10 (3H, m), 6.95-6.99 (1H, q),
5.57 (2H, d), 5.15 (2H, d), 2.65 (H, t), 2.30 (3H, s), 2.15 (1H, s), 1.85 (3H, d) 1.73 (2H, m),
1.68 (6H, d), 0.96 (3H, t).
(14) QR2034:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl]
The synthesis of imidazole-5-carboxylic acid (3- nitrate -1,2,5- oxadiazoles -2- oxo -4- base) methyl esters
Synthetic method is with (7) item in embodiment 1, and preparing raw material, { [2'- (1H-TETRAZOLE -5- base) joins by 2- ethyoxyl -1-
Benzene -4- base] methyl } -1H- benzimidazole -7- carboxylic acid is changed to 4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H-
Tetrazolium -5- phenyl) benzyl] imidazole-5-carboxylic acid, structure confirms through hydrogen nuclear magnetic resonance spectrogram.H-NMR(CDCl3, 400MHz) and δ:
7.83-7.88 (2H, m), 7.65-7.74 (2H, d), 7.42 (2H, m), 7.12-7.16 (3H, m), 5.54 (2H, d), 5.10
(2H, d), 4.91 (2H, s), 2.69 (H, t), 2.30 (1H, s), 1.71 (2H, m), 1.60 (6H, d), 1.01 (3H, t).
(15) QR2109:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- 4- [2- (dihydro -1,2 5- oxo -4,5-,
4- oxadiazoles -3)-phenyl] benzyl imidazole-5-carboxylic acid (phenyl -1,2,5 4-,-oxadiazoles -2- oxo -3-) methyl esters synthesis
Synthetic method is with (1) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to 4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- { 4- [2- (5- oxygen
Generation -4,5- dihydro -1,2,4- oxadiazoles -3)-phenyl] benzyl } imidazole-5-carboxylic acid, structure confirms through hydrogen nuclear magnetic resonance spectrogram.
H-NMR(CDCl3, 400MHz) and δ: 7.97 (1H, m), 7.85-7.89 (1H, m), 7.71-7.76 (1H, m), 7.48-7.54 (3H,
M), 7.30-7.38 (7H, m), 7.08-7.12 (2H, m), 5.45 (2H, d), 5.11 (2H, d), 2.63 (H, t), 2.32 (1H,
S), 1.71 (2H, m), 1.66 (6H, d), 1.04 (3H, t).
4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- { 4- [2- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -
3)-phenyl] benzyl imidazole-5-carboxylic acid preparation method refer to Journal of medicinal chemistry.1996,39
(26): 5228-5235 and patent CN1045770.
(16) QR2117:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- 4- [2- (dihydro -1,2 5- oxo -4,5-,
4- oxadiazoles -3)-phenyl] benzyl } imidazole-5-carboxylic acid (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen) methyl esters
Synthesis
Synthetic method is with (2) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to 4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- { 4- [2- (5- oxygen
Generation -4,5- dihydro -1,2,4- oxadiazoles -3)-phenyl] benzyl } imidazole-5-carboxylic acid, structure confirms through hydrogen nuclear magnetic resonance spectrogram.
H-NMR(CDCl3, 400MHz) and δ: 7.95 (1H, m), 7.87-7.89 (1H, m), 7.73-7.78 (1H, m), 7.45-7.52 (3H,
M), 7.32-7.36 (1H, m), 7.06-7.10 (3H, m), 5.48 (2H, d), 5.06 (2H, d), 2.67 (H, t), 2.38 (3H,
S), 2.29 (6H, s), 2.02 (1H, s), 1.73 (2H, m), 1.63 (6H, d), 0.96 (3H, t).
(17) QR2119:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- 4- [2- (dihydro -1,2 5- oxo -4,5-,
4- oxadiazoles -3)-phenyl] benzyl imidazole-5-carboxylic acid (phenyl -1,2,5 4-,-oxadiazoles -2- oxo -3-) methyl esters synthesis
Synthetic method is with (3) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to 4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- { 4- [2- (5- oxygen
Generation -4,5- dihydro -1,2,4- oxadiazoles -3)-phenyl] benzyl } imidazole-5-carboxylic acid, structure confirms through hydrogen nuclear magnetic resonance spectrogram.
H-NMR(CDCl3, 400MHz) and δ: 7.98 (1H, m), 7.84-7.88 (1H, m), 7.71-7.77 (1H, m), 7.42-7.54 (3H,
M), 7.30-7.34 (1H, m), 7.09-7.13 (2H, m), 6.73 (H, q), 5.52 (2H, d), 5.12 (2H, d), 2.63 (H, t),
2.34 (3H, s), 2.26 (6H, s), 2.00 (1H, s), 1.87 (3H, d), 1.75 (2H, m), 1.60 (6H, d), 0.99 (3H, t).
(18) QR2120:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- 4- [2- (dihydro -1,2 5- oxo -4,5-,
4- oxadiazoles -3)-phenyl] benzyl } imidazole-5-carboxylic acid (3- methyl-1,2,5- oxadiazoles -2- oxo -4- methoxyl group-oxo carbon
Acyl-oxygen) methyl esters synthesis
Synthetic method is with (4) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to 4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- { 4- [2- (5- oxygen
Generation -4,5- dihydro -1,2,4- oxadiazoles -3)-phenyl] benzyl } imidazole-5-carboxylic acid, structure confirms through hydrogen nuclear magnetic resonance spectrogram.
H-NMR(CDCl3, 400MHz) and δ: 7.90 (1H, m), 7.85-7.88 (1H, m), 7.74-7.79 (1H, m), 7.43-7.58 (3H,
M), 7.37-7.40 (1H, m), 7.08-7.14 (3H, m), 5.42 (2H, d), 5.10 (2H, d), 2.60 (H, t), 2.45 (3H,
S), 2.12 (1H, s), 1.68 (2H, m), 1.59 (6H, d), 1.08 (3H, t).
(19) QR2121:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- 4- [2- (dihydro -1,2 5- oxo -4,5-,
4- oxadiazoles -3)-phenyl] benzyl } imidazole-5-carboxylic acid [1- (3- methyl-1,2,5- oxadiazoles -2- oxide -4- methoxyl group-oxygen
For phosphinylidyne oxygen)] synthesis of ethyl ester
Synthetic method is with (5) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to 4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- { 4- [2- (5- oxygen
Generation -4,5- dihydro -1,2,4- oxadiazoles -3)-phenyl] benzyl } imidazole-5-carboxylic acid, structure confirms through hydrogen nuclear magnetic resonance spectrogram.
H-NMR(CDCl3, 400MHz) and δ: 7.97 (1H, m), 7.82-7.86 (1H, m), 7.76-7.78 (1H, m), 7.45-7.52 (3H,
M), 7.32-7.35 (1H, m), 7.08-7.11 (2H, m), 6.75 (H, q), 5.50 (2H, d), 5.03 (2H, d), 2.67 (H, t),
2.39 (3H, s), 2.16 (1H, s), 1.72 (3H, d), 1.68 (2H, m), 1.59 (6H, d), 0.96 (3H, t).
(20) QR2123:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- 4- [2- (dihydro -1,2 5- oxo -4,5-,
4- oxadiazoles -3)-phenyl] benzyl imidazole-5-carboxylic acid (3- methyl-1,2,5- oxadiazoles -2- oxo -4- base) methyl esters synthesis
Synthetic method is with (6) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to 4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- { 4- [2- (5- oxygen
Generation -4,5- dihydro -1,2,4- oxadiazoles -3)-phenyl] benzyl } imidazole-5-carboxylic acid, structure confirms through hydrogen nuclear magnetic resonance spectrogram.
H-NMR(CDCl3, 400MHz) and δ: 7.95 (1H, m), 7.84-7.91 (1H, m), 7.77-7.79 (1H, m), 7.48-7.53 (3H,
M), 7.35-7.38 (1H, m), 7.10-7.13 (2H, m), 5.63 (2H, d), 5.21 (2H, d), 2.69 (H, t), 2.45 (3H,
S), 2.21 (1H, s), 1.64 (2H, m), 1.67 (6H, d), 1.12 (3H, t).
(21) QR2136:4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- 4- [2- (dihydro -1,2 5- oxo -4,5-,
4- oxadiazoles -3)-phenyl] benzyl imidazole-5-carboxylic acid (3- itrile group -1,2,5- oxadiazoles -2- oxo -4- base) methyl esters synthesis
Synthetic method is with (7) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to 4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- { 4- [2- (5- oxygen
Generation -4,5- dihydro -1,2,4- oxadiazoles -3)-phenyl] benzyl } imidazole-5-carboxylic acid, structure confirms through hydrogen nuclear magnetic resonance spectrogram.
H-NMR(CDCl3, 400MHz) and δ: 7.99 (1H, m), 7.81-7.85 (1H, m), 7.73-7.75 (1H, m), 7.43-7.50 (3H,
M), 7.31-7.34 (1H, m), 7.07-7.10 (2H, m), 5.59 (2H, d), 5.16 (2H, d), 2.62 (H, t), 2.13 (1H,
S), 1.58 (2H, m), 1.63 (6H, d), 1.01 (3H, t).
(22) QR3009:N- [1- carboxylic acid (phenyl -1,2,5 4-,-oxadiazoles -2- oxo -3- base) methyl esters -2- methyl-prop
Base -1- base]-N- valeryl-N- [2'- (1H-TETRAZOLE -5- base)-biphenyl -4- base-methyl]-amine synthesis
Synthetic method is with (1) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to N- (1- carboxylic acid -2- methyl-propyl -1- base)-N- valeryl-N- [2 ' -
(1H-TETRAZOLE -5- base)-biphenyl -4- base-methyl]-amine, structure confirms through hydrogen nuclear magnetic resonance spectrogram.H-NMR (CDCl3,
400MHz) δ: 7.79-7.82 (1H, m), 7.69-7.76 (4H, m), 7.36-7.49 (7H, m), 7.18 (2H, m), 5.54 (2H,
S), 4.86 (3H, m), 3.25 (H, m), 2.28 (1H, t), 1.68 (2H, m), 1.39 (2H, m), 0.94-1.13 (9H, m).
N- (1- carboxylic acid -2- methyl-propyl -1- base)-N- valeryl-N- [2 '-(1H-TETRAZOLE -5- base)-biphenyl -4- bases-first
Base]-amine synthetic method referenced patent US5399578.
(23) QR3017:N- [1- carboxylic acid (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen) methyl esters -2- methyl
Propyl -1- base]-N- valeryl-N- [2'- (1H-TETRAZOLE -5- base)-biphenyl -4- base-methyl]-amine synthesis
Synthetic method is with (2) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to N- (1- carboxylic acid -2- methyl-propyl -1- base)-N- valeryl-N- [2 ' -
(1H-TETRAZOLE -5- base)-biphenyl -4- base-methyl]-amine, structure confirms through hydrogen nuclear magnetic resonance spectrogram.H-NMR(CDCl3,
400MHz) δ: 7.80-7.83 (1H, m), 7.72-7.75 (2H, m), 7.37-7.45 (4H, m), 7.15 (2H, m), 6.98 (2H,
S), 5.59 (2H, s), 4.88 (3H, m), 3.15 (H, m), 2.34 (3H, s), 2.31 (1H, t), 2.25 (6H, s), 1.65 (2H,
M), 1.43 (2H, m), 0.97-1.15 (9H, t).
(24) QR3019:N- { 1- carboxylic acid [1- (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen)] acetyl -2-
Methyl-propyl -1- base }-N- valeryl-N- [2 '-(1H-TETRAZOLE -5- base)-biphenyl -4- bases-methyl]-amine synthesis
Synthetic method is with (3) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to N- (1- carboxylic acid -2- methyl-propyl -1- base)-N- valeryl-N- [2 ' -
(1H-TETRAZOLE -5- base)-biphenyl -4- base-methyl]-amine, structure confirms through hydrogen nuclear magnetic resonance spectrogram.H-NMR(CDCl3,
400MHz) δ: 7.80-7.83 (1H, m), 7.72-7.75 (2H, m), 7.37-7.45 (4H, m), 7.15 (2H, m), 6.98 (2H,
S), 6.72 (H, q), 5.59 (2H, s), 4.88 (3H, m), 3.15 (H, m), 2.34 (3H, s), 2.31 (1H, t), 2.25 (6H,
S), 1.86 (3H, d), 1.65 (2H, m), 1.43 (2H, m), 0.96-1.13 (9H, t).
(25) QR3020:N- [1- carboxylic acid (3- methyl-1,2,5- oxadiazoles -2- oxo -4- methoxyl group-oxo phosphinylidyne oxygen)
Formyl -2- methyl-propyl -1- base]-N- valeryl-N- [2 '-(1H-TETRAZOLE -5- base)-biphenyl -4- bases-methyl]-amine synthesis
Synthetic method is with (4) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to N- (1- carboxylic acid -2- methyl-propyl -1- base)-N- valeryl-N- [2 ' -
(1H-TETRAZOLE -5- base)-biphenyl -4- base-methyl]-amine, structure confirms through hydrogen nuclear magnetic resonance spectrogram.H-NMR(CDCl3,
400MHz) δ: 7.86-7.89 (1H, m), 7.75-7.79 (2H, m), 7.39-7.47 (4H, m), 7.18 (2H, m), 6.95 (2H,
S), 5.53 (2H, s), 4.94 (3H, m), 3.21 (H, m), 2.38 (3H, s), 2.28 (1H, t), 1.67 (2H, m), 1.48 (2H,
M), 0.95-1.14 (9H, t).
(26) QR3021:N- { 1- carboxylic acid [1- (3- methyl-1,2,5- oxadiazoles -2- oxide -4- methoxyl group-oxo carbon
Acyl-oxygen)] ethyl ester -2- methyl-propyl -1- base }-N- valeryl-N- [2'- (1H-TETRAZOLE -5- base)-biphenyl -4- base-methyl]-amine
Synthesis
Synthetic method is with (5) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to N- (1- carboxylic acid -2- methyl-propyl -1- base)-N- valeryl-N- [2 ' -
(1H-TETRAZOLE -5- base)-biphenyl -4- base-methyl]-amine, structure confirms through hydrogen nuclear magnetic resonance spectrogram.H-NMR(CDCl3,
400MHz) δ: 7.82-7.85 (1H, m), 7.70-7.73 (2H, m), 7.39-7.45 (4H, m), 7.13 (2H, m), 6.94 (2H,
S), 6.79 (H, q), 5.65 (2H, s), 4.84 (3H, m), 3.22 (H, m), 2.38 (3H, s), 2.30 (1H, t), 1.89 (3H,
D), 1.60 (2H, m), 1.47 (2H, m), 0.94-1.09 (9H, t).
(27) QR3034:N- [1- carboxylic acid (3- nitrate -1,2,5- oxadiazoles -2- oxo -4- base) methyl esters -2- methyl
Propyl -1- base]-N- valeryl-N- [2 '-(1H-TETRAZOLE -5- base)-biphenyl -4- bases-methyl]-amine synthesis
Synthetic method is with (7) item in embodiment 1, and preparing raw material, { [2'- (1H-TETRAZOLE -5- base) joins by 2- ethyoxyl -1-
Benzene -4- base] methyl } -1H- benzimidazole -7- carboxylic acid is changed to N- (1- carboxylic acid -2- methyl-propyl -1- base)-N- valeryl-N-
[2 '-(1H-TETRAZOLE -5- base)-biphenyl -4- bases-methyl]-amine, structure are confirmed through hydrogen nuclear magnetic resonance spectrogram.H-NMR(CDCl3,
400MHz) δ: 7.88-7.93 (1H, m), 7.76-7.79 (2H, m), 7.42-7.48 (4H, m), 7.15 (2H, m), 6.93 (2H,
S), 5.58 (2H, s), 5.18 (2H, s), 4.80 (3H, m), 3.28 (H, m), 2.33 (3H, s), 2.22 (1H, t), 1.62 (2H,
M), 1.45 (2H, m), 0.98-1.19 (9H, t).
(28) QR3109:N- [1- carboxylic acid (phenyl -1,2,5 4-,-oxadiazoles -2- oxo -3- base) methyl esters -2- methyl-prop
Base -1- base]-N- valeryl-N- [2'- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-methyl] -
The synthesis of amine
Synthetic method is with (1) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to N- (1- carboxylic acid -2- methyl-propyl -1- base)-N- valeryl-N- [2 ' -
(5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-methyl]-amine, structure is through hydrogen nuclear magnetic resonance spectrogram
Confirmation.H-NMR(CDCl3, 400MHz) and δ: 7.82-7.86 (1H, m), 7.76-7.80 (1H, m), 7.57-7.63 (3H, m),
7.42-7.46 (7H, m), 7.24 (2H, m), 5.64 (2H, s), 4.93 (3H, m), 3.32 (1H, m), 2.57 (1H, t), 1.74
(2H, m), 1.45 (2H, m), 0.99-1.18 (9H, m).
N- (1- carboxylic acid -2- methyl-propyl -1- base)-N- valeryl-N- [2 '-(5- oxo -4,5- dihydro -1,2,4- evils two
Azoles -3- base)-biphenyl -4- base-methyl]-amine synthetic method referenced patent US5399578.
(29) QR3117:N- [1- carboxylic acid (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen) methyl esters -2- methyl
Propyl -1- base]-N- valeryl-N- [2'- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-first
Base]-amine synthesis
Synthetic method is with (2) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to N- [1- carboxylic acid -2- methyl-propyl -1- base]-N- valeryl-N- [2'-
(5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-methyl]-amine, structure is through hydrogen nuclear magnetic resonance spectrogram
Confirmation.H-NMR(CDCl3, 400MHz) and δ: 7.88-7.90 (1H, m), 7.78-7.82 (1H, m), 7.59-7.61 (1H, m),
7.40-7.45 (3H, m), 7.32 (1H, m), 7.24 (2H, m), 7.03 (2H, d), 5.57 (2H, s), 4.89 (3H, m), 3.12
(H, m), 2.36 (3H, s), 2.32 (1H, t), 2.27 (6H, s), 1.68 (2H, m), 1.40 (2H, m), 0.99-1.18 (9H, t).
(30) QR3119:N- { 1- carboxylic acid [1- (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester -2-
Methyl-propyl -1- base }-N- valeryl-N- [2'- (5- oxo -4,5- dihydro -1,2,4-Diazole -3- base)-biphenyl -4- base -
Methyl]-amine synthesis
Synthetic method is with (3) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to N- (1- carboxylic acid -2- methyl-propyl -1- base)-N- valeryl-N- [2 ' -
(5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-methyl]-amine, structure is through hydrogen nuclear magnetic resonance spectrogram
Confirmation.δ: 7.89-7.93 (1H, m), 7.77-7.80 (1H, m), 7.56-7.59 (1H, m), 7.41-7.44 (3H, m), 7.36
(1H, m), 7.26 (2H, m), 6.70 (H, q), 5.56 (2H, s), 4.87 (3H, m), 3.20 (H, m), 2.38 (3H, s), 2.37
(1H, t), 2.27 (6H, s), 1.89 (3H, d), 1.67 (2H, m), 1.48 (2H, m), 0.99-1.16 (9H, t).
(31) QR3120:N- [1- carboxylic acid (3- methyl-1,2,5- oxadiazoles -2- oxo -4- methoxyl group-oxo phosphinylidyne oxygen)
Methyl esters -2- methyl-propyl -1- base]-N- valeryl-N- [2'- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-connection
Benzene -4- base-methyl]-amine synthesis
Synthetic method is with (4) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to N- (1- carboxylic acid -2- methyl-propyl -1- base)-N- valeryl-N- [2 ' -
(5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-methyl]-amine, structure is through hydrogen nuclear magnetic resonance spectrogram
Confirmation.δ: 7.87-7.91 (1H, m), 7.74-7.78 (1H, m), 7.58-7.64 (1H, m), 7.44-7.48 (3H, m), 7.38
(1H, m), 7.29 (2H, m), 6.87 (2H, s), 5.57 (2H, s), 4.93 (3H, m), 3.24 (H, m), 2.37 (3H, s), 2.32
(1H, t), 1.72 (2H, m), 1.43 (2H, m), 0.93-1.11 (9H, t).
(32) QR3121:N- { 1- carboxylic acid [1- (3- methyl-1,2,5- oxadiazoles -2- oxide -4- methoxyl group-oxo carbon
Acyl-oxygen)] acetyl -2- methyl-propyl -1- base }-N- valeryl-N- [2'- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3-
Base)-biphenyl -4- base-methyl]-amine synthesis
Synthetic method is with (5) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to N- (1- carboxylic acid -2- methyl-propyl -1- base)-N- valeryl-N- [2 ' -
(5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-methyl]-amine, structure is through hydrogen nuclear magnetic resonance spectrogram
Confirmation.δ: 7.85-7.90 (1H, m), 7.72-7.76 (1H, m), 7.58-7.63 (1H, m), 7.46-7.50 (3H, m), 7.36
(1H, m), 7.24 (2H, m), 6.83 (H, q), 5.69 (2H, s), 4.97 (3H, m), 3.29 (H, m), 2.38 (3H, s), 2.28
(1H, t), 1.85 (3H, d), 1.67 (2H, m), 1.54 (2H, m), 0.93-1.12 (9H, t).
(33) QR3123:N- [1- carboxylic acid (3- methyl-1,2,5- oxadiazoles -2- oxo -4- base) methyl esters -2- methyl-propyl -
1- yl]-N- valeryl-N- [2'- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-methyl]-amine
Synthesis
Synthetic method is with (6) item in embodiment 1, by raw material 2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -
4- yl] methyl } -1H- benzimidazole -7- carboxylic acid is changed to N- [1- carboxylic acid -2- methyl-propyl -1- base]-N- valeryl-N- [2'-
(5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-methyl]-amine, structure is through hydrogen nuclear magnetic resonance spectrogram
Confirmation.δ: 7.82-7.88 (1H, m), 7.72-7.76 (1H, m), 7.53-7.57 (1H, m), 7.42-7.49 (3H, m), 7.32
(1H, m), 7.18 (2H, m), 5.69 (2H, s), 5.31 (2H, s), 4.81 (3H, m), 3.39 (H, m), 2.25 (1H, t), 1.58
(2H, m), 1.48 (2H, m), 0.94-1.13 (9H, t).
(34) QR3134:N- [1- carboxylic acid (3- nitrate -1,2,5- oxadiazoles -2- oxo -4- base) methyl esters -2- methyl
Propyl -1- base]-N- valeryl-N- [2'- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-first
Base]-amine synthesis
Synthetic method is with (7) item in embodiment 1, and preparing raw material, { [2'- (1H-TETRAZOLE -5- base) joins by 2- ethyoxyl -1-
Benzene -4- base] methyl } -1H- benzimidazole -7- carboxylic acid is changed to N- [1- carboxylic acid -2- methyl-propyl -1- base]-N- valeryl-N-
[2'- (5- oxo -4,5- dihydro -1,2,4- oxadiazoles -3- base)-biphenyl -4- base-methyl]-amine, structure is through hydrogen nuclear magnetic resonance
Spectrogram confirmation.δ: 7.88-7.92 (1H, m), 7.76-7.78 (1H, m), 7.55-7.60 (1H, m), 7.48-7.53 (3H, m),
7.39 (1H, m), 7.25 (2H, m), 5.62 (2H, s), 5.25 (2H, s), 4.87 (3H, m), 3.32 (H, m), 2.38 (3H, s),
2.26 (1H, t), 1.57 (2H, m), 1.41 (2H, m), 0.95-1.21 (9H, t).
Embodiment 2
Test-compound (34 kinds of noval chemical compounds prepared by embodiment 1) single-dose is tested to the drop of renal hypertensive rat
Pressure effect
Method: Wistar rat (is provided, Wuhan, Hubei) by Disease Prevention Control Center, Hubei Prov, male, weight,
180-200g is randomly divided into 3 groups, and negative control group (0.5%CMC-Na), positive controls are (with the Olmesartan of 1.0ml/kg
Ester is positive drug) and test-compound group (dosage 1.0mg/kg, in addition to number be QR3009, QR3017, QR3019,
The dosage of QR3020, QR3021, QR3034, QR3109, QR3117, QR3119, QR3120, QR3123 and QR3134 is
Other than 10mg/kg, all drugs are prepared in 0.5%CMC-Na), every group of 6-8 animal.The side arteria renalis is ligatured, is formed
Two-kidney One-clip type renal hypertensive rat (RHR) model, measures weekly a blood pressure, continuous surrounding, blood pressure stabilization liter after operation
The rat of high 4kPa is the successful rat of modeling.Before measuring blood pressure, rat is heated with 39 DEG C of circulator bath tail sleeve to rat-tail, makes tail
After portion's blood vessel dilatation, with tail sleeve method (BP2010A non-invasive blood pressure instrument, Beijing Ji'an get Er Science and Technology Ltd., Haidian District, Beijing City
Ten street No.1 of Shangdi) measurement rat administration before, after gastric infusion 1,3,5,7,10 and 10h blood pressure, each time point survey three times
It is averaged.Pressure value × 100% before maximum blood pressure lowering value/administration after maximum hypotensive activity (%)=administration.
Experimental result: it is shown in Table 1
Influence of 1 test drug of table to the antihypertensive effect of renal hypertensive rat
Conclusion: in ligation arteria renalis Hypertension Rats animal model, 34 kinds of compounds prepared by the present invention are shown not
With the hypotensive activity of degree.
Embodiment 3
Detect influence of the test-compound (34 kinds of noval chemical compounds prepared by embodiment 1) to rat lipid metaboli
Method: Wistar rat (is provided, Wuhan, Hubei) by Disease Prevention Control Center, Hubei Prov, male,Weight,
180-200g is randomly divided into 5 groups, and negative control group (0.5%CMC-Na), positive controls are (with the Olmesartan of 1.0ml/kg
Ester is positive drug) and test-compound group (1.0mg/kg, in addition to number be QR3009, QR3017, QR3019, QR3020,
The dosage of QR3021, QR3034, QR3109, QR3117, QR3119, QR3120, QR3123 and QR3134 are 10mg/kg, are owned
Drug is prepared in 0.5%CMC-Na), every group of 5-6 animal.High lipid food is fed groups of animals 8 weeks, at the 5th week, yin
Property control group uses the physiological saline stomach-filling of 0.5%CMC-Na daily, and positive controls and tested group use positive drug or tested daily
Medicine (1.0mg/kg) carries out stomach-filling.After feeding 8 weeks, that anesthetized rat of amobarbital, abdominal aortic blood divides after collecting blood
From serum, freeze to be measured.Internal organs and perirenal fat are separated after rat extracting blood.It is solid with the total gallbladder of full automatic biochemical apparatus enzymatic assays serum
Alcohol (TC).
As a result: being shown in Table 2
Influence of 2 test drug of table to experimental rat weight, perirenal fat and total cholesterol
Conclusion: the weight and adipose tissue for the reduction high fat diet rat that 34 kinds of test-compounds can be different degrees of, and
It is adjustable lipid metaboli.
Embodiment 4
Antihypertensive effect of the oral QR1019 sylvite single-dose to renal hypertensive rat
Wistar rat (is provided, Wuhan, Hubei) by Disease Prevention Control Center, Hubei Prov, male, weight, 180-
200g is randomly divided into 5 groups, and negative control group (0.5%CMC-Na), positive controls are (with the Azilsartan potassium of 1.0mg/kg
Salt is positive drug) and test-compound QR1019 sylvite (1.0mg/kg), every group of 6-8 animal.The side arteria renalis is ligatured,
Two-kidney One-clip type renal hypertensive rat (RHR) model is formed, measures a blood pressure after operation weekly, continuous surrounding, blood pressure is steady
Surely the rat for increasing 4kPa is the successful rat of modeling.Before measuring blood pressure, rat is heated with 39 DEG C of circulator bath tail sleeve to rat-tail,
After expanding tail veins,With tail sleeve method (BP2010A non-invasive blood pressure instrument, Beijing Ji'an get Er Science and Technology Ltd., Beijing sea
Ten street No.1 of shallow lake area Shangdi) measurement rat administration before, after gastric infusion 1,3,5,7,10 and 10h blood pressure and heart rate, Mei Geshi
Between point survey be averaged three times.Pressure value * 100% before maximum blood pressure lowering value/administration after maximum hypotensive activity (%)=administration.
Table 5. takes orally QR1019 sylvite and positive drug to the antihypertensive effect of renal hypertensive rat
As a result with conclusion: the QR1019 sylvite of test-compound prepared by the present invention is right compared to positive under Isodose
There is significant antihypertensive effect according to group, and it is also significantly better than positive controls to the adjusting of heart rate.
Embodiment 5
34 Ar-CH prepared by embodiment 12In-X compound any one, lactose and microcrystalline cellulose premix
5min stirs 3rpm, cuts 30rpm；PVP k30 is dissolved in suitable quantity of water and (is dissolved in the conversion of 2g water by 0.36g PVP k30), is opened
Stirring cutting is opened, while binder aqueous solution is added, softwood crosses the granulation of 30 meshes,60 DEG C of dryings of wet granular to moisture 1%-2%,
24 mesh sieves, dry particl weighing, croscarmellose sodium and magnesium stearate are added in dry particl, are uniformly mixed, pressure
Tablet is made in piece.
Embodiment 6
34 Ar-CH prepared by the embodiment 1 of micronization of learning from else's experience2Any one in-X compound, lactose, microcrystalline cellulose
Element, low-substituted hydroxypropyl cellulose mix 5 minutes in wet granulator, and the adhesive for being gradually added into 5% PVP K30 is molten
Then liquid adds suitable purified water, pelletize 3 minutes, crosses 24 mesh screens, wet granular is placed in pallet, in 55 DEG C of baking
Dry in case, rewinding, the particle of drying crosses 20 mesh whole grains, mixes 15 with additional crospovidone, superfine silica gel powder, magnesium stearate
Minute, tabletting is to get dispersible tablet.
The composition of raw materials of the present embodiment is as follows:
Embodiment 7
34 Ar-CH prepared by embodiment 12In-X compound any one, Dioleoyl Phosphatidylcholine, gallbladder it is solid
Alcohol, NaGC and sojasterol are dissolved in the in the mixed solvent of ethyl alcohol and n-hexane, are uniformly mixed, in rotary film evaporator
On organic solvent is removed under reduced pressure, obtain immobilized artificial membrane；Citric acid-sodium citrate buffer solution that pH is 6.0 is added, shakes, stirring
30 minutes, make the complete aquation of immobilized artificial membrane, with the homogeneous emulsification of tissue mashing machine's high speed 10 minutes, 0.45 μm of filtering with microporous membrane, system
The liposome powder of drug containing is made in liposome turbid liquor, spray drying, then by itself and mannitol, microcrystalline cellulose and crosslinking
Sodium carboxymethylcellulose mixing is crossed 60 meshes and is uniformly mixed, and hydroxypropyl cellulose is added, and ethanol solution prepares softwood, crosses 20 mesh
Dry particl and magnesium stearate are uniformly mixed by sieve granulation, 50 DEG C of dryings, cross 18 mesh sieves, tabletting, and liposome is made in coating
Tablet.
Embodiment 8
34 Ar-CH prepared by Example 12Any one in-X compound and Compritol 888 ATO
(Compritol), calcium phosphate dibasic anhydrous, lactose mixing, sufficiently stir evenly, add adhesive PVP K30 solution, mix in high-speed stirred
Wet granular is made in granulator, is then dried；Sieving whole grain, is added carbomer (CarbopolR971P), magnesium stearate
And talcum powder, it mixes, tabletting.
The composition of raw materials of the present embodiment is as follows:
Claims (8)
1. general formula is Ar-CH2The compound of-X or its pharmaceutically acceptable salt:
Wherein, X is representedOr
R0It is C1-4Alkyl；
R1a representative-CH2OC (=O) OR1aa、-CH(C1-4Alkyl) OC (=O) OR1aa、
R1aaIt represents
R6Represent phenyl, itrile group, trifluoromethyl ,-C1-4Alkylene nitrate or C1-4Alkyl；
R2And R3It is identical or different, and respectively represent hydrogen or C1-4Alkyl；
Ar isWherein R1For tetrazole radical -5- base.
2. the sylvite of compound described in claim 1.
3. compound:
2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic acid (4- phenyl -
1,2,5,-oxadiazoles -2- oxo -3- base) methyl esters,
2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic acid (3,5,6- tri-
Methylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen) methyl esters,
2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic acid [1- (3,5,
6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester,
2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic acid (3- methyl -
1,2,5- oxadiazoles -2- oxo -4- methoxyl group-oxo phosphinylidyne oxygen) methyl esters,
2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic acid [1- (3- first
Base -1,2,5- oxadiazoles -2- oxide -4- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester,
2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic acid (3- methyl -
1,2,5- oxadiazoles -2- oxide -4- base) methyl esters,
2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic acid (3- nitric acid first
Base -1,2,5- oxadiazoles -2- oxo -4- base) methyl esters,
2- ethyoxyl -1- { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic acid (3- itrile group -
1,2,5- oxadiazoles -2- oxo -4- base) methyl esters,
4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] imidazole-5-carboxylic acid (4- benzene
Base -1,2,5,-oxadiazoles -2- oxo -3-) methyl esters,
4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] imidazole-5-carboxylic acid (3,5,
6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen) methyl esters,
4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] imidazole-5-carboxylic acid [1-
(3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester,
4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] imidazole-5-carboxylic acid (3- first
Base -1,2,5- oxadiazoles -2- oxo -4- methoxyl group-oxo phosphinylidyne oxygen) methyl esters,
4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] imidazole-5-carboxylic acid [1-
(3- methyl-1,2,5- oxadiazoles -2- oxide -4- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester,
4- (1- hydroxyl -1- Methylethyl) -2- propyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] imidazole-5-carboxylic acid (3- nitre
Acid methyl -1,2,5- oxadiazoles -2- oxo -4- base) methyl esters or its pharmaceutically acceptable salt.
Compound 2- ethyoxyl -1- 4. { [2'- (1H-TETRAZOLE -5- base) biphenyl -4- base] methyl } -1H- benzimidazole -7- carboxylic acid
The sylvite of [1- (3,5,6- trimethylpyrazine -2- methoxyl group-oxo phosphinylidyne oxygen)] ethyl ester.
5. any compound is used to prepare the purposes of drug in claim 1-4, the drug is needed for treating or preventing
It will selectivity excitement AT2The illness of receptor, treatment AngII endogenous generate insufficient illness, and treatment needs to enhance AngII effect
Illness.
6. any compound is used to prepare the purposes of drug in claim 1-4, the drug is for treating hypertension, the heart
Force failure, myocardial infarction, atherosclerosis, diabetic complication, dyslipidemia or hypertriglyceridemia.
7. a kind of pharmaceutical composition, it includes the compound or its pharmaceutically acceptable salt any in claim 1-4,
And it chooses any one kind of them or a variety of pharmaceutically acceptable carriers and/or diluent.
8. peroral dosage form, wherein any compound in the claim 1-4 containing therapeutically effective amount, wherein the dosage form is
Tablet, dispersible tablet, Liposomal formulation or sustained release preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510124540.5A CN106032378B (en) | 2015-03-20 | 2015-03-20 | New A RB compound and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510124540.5A CN106032378B (en) | 2015-03-20 | 2015-03-20 | New A RB compound and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106032378A CN106032378A (en) | 2016-10-19 |
| CN106032378B true CN106032378B (en) | 2019-10-25 |
Family
ID=57148768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510124540.5A Active CN106032378B (en) | 2015-03-20 | 2015-03-20 | New A RB compound and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106032378B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114177163B (en) * | 2022-01-12 | 2023-05-02 | 刘树民 | Medicine for treating hypertension |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1067890A (en) * | 1991-06-27 | 1993-01-13 | 武田药品工业株式会社 | Heterogeneous ring compound, its preparation and application |
| CN1079966A (en) * | 1991-06-27 | 1993-12-29 | 武田药品工业株式会社 | Heterogeneous ring compound, its preparation and application |
| CN1946717A (en) * | 2004-02-25 | 2007-04-11 | 武田药品工业株式会社 | Benzimidazole derivatives and their use as AII receptor antagonists |
| CN103709154A (en) * | 2012-09-28 | 2014-04-09 | 武汉启瑞药业有限公司 | Benzimidazole derivative and its preparation method and medical application |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012090043A1 (en) * | 2010-12-29 | 2012-07-05 | Jubilant Life Sciences Limited | Novel solid state forms of azilsartan medoxomil and preparation thereof |
-
2015
- 2015-03-20 CN CN201510124540.5A patent/CN106032378B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1067890A (en) * | 1991-06-27 | 1993-01-13 | 武田药品工业株式会社 | Heterogeneous ring compound, its preparation and application |
| CN1079966A (en) * | 1991-06-27 | 1993-12-29 | 武田药品工业株式会社 | Heterogeneous ring compound, its preparation and application |
| CN1946717A (en) * | 2004-02-25 | 2007-04-11 | 武田药品工业株式会社 | Benzimidazole derivatives and their use as AII receptor antagonists |
| CN103709154A (en) * | 2012-09-28 | 2014-04-09 | 武汉启瑞药业有限公司 | Benzimidazole derivative and its preparation method and medical application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106032378A (en) | 2016-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104066731B (en) | 2-Benzyl, 3-(pyrimidin-2-yl)-substituted pyrazoles useful as SGC stimulators | |
| CN103709154B (en) | Benzimidazole derivative and its preparation method and medical application | |
| CN101511820A (en) | Double benzimidazole derivative with PPAR gamma excitomotor activity and application thereof | |
| EP1210343A2 (en) | Benzoic acid derivatives and their use as ppar receptor agonists | |
| CN102159208A (en) | 6-1h-imidazo-quinazoline and quinolines derivatives, new mao inhibitors and imidazoline receptor ligands | |
| JP2018526417A (en) | Compound for the treatment or prevention of hyperuricemia or gout | |
| KR20140027833A (en) | Composition comprising a pyrazole derivative for prevention or treatment of kidney disease | |
| WO2008110062A1 (en) | Compounds with partial agonist activity of pparϝ and application thereof | |
| RU2126401C1 (en) | Benzimidazole derivatives, tautomers or salts thereof and drug having antagonistic angiotensine ii effect | |
| CN103087044A (en) | Method for preparing benzimidazole heterocyclic compound | |
| AU2010211753B2 (en) | Phenylimidazole compounds | |
| CN106032378B (en) | New A RB compound and application thereof | |
| CN101798300B (en) | N-phenylindole methyl substituted bis-benzimidazole derivative and application thereof in reducing blood pressure and the like | |
| CN105153141B (en) | Benzimidizole derivatives and preparation method thereof and medical usage | |
| JP7092356B2 (en) | Biarylurea derivatives or salts thereof, and their preparation methods and uses | |
| CN101768149B (en) | Beta- aminoketone (alkamine) derivatives and use thereof | |
| WO2007143951A1 (en) | COMPOUNDS WITH THE ACTIVITY OF PPARγ AGONIST AND APPLICATION THEREOF | |
| CN107155325B (en) | Novel amino-phenyl-sulfonyl-acetate derivatives and their uses | |
| CN102167685B (en) | 4-(2'-n-butyl-4,5-disubstituted-2,4'-bis-imidazole-3'-methyl) benzoic acid derivative | |
| EP0686631A1 (en) | Pyrimidine derivatives and pharmaceutical composition | |
| CN106749220B (en) | A kind of 6'-substituted benzimidazole-4-substituted methyl indole derivative and its preparation and application | |
| CN104109119B (en) | N '-sweet-smelling formacyls neighbour's pyridine hydrazide derivatives and its preparation method and pharmaceutical composition and purposes | |
| JPS6182A (en) | Quinolone cardiac stimulant | |
| CN103012314A (en) | Sulfonamide compound and preparation method as well as application thereof | |
| CN108129486A (en) | Pyrimidone derivatives and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Novel ARB compound and application thereof Effective date of registration: 20200630 Granted publication date: 20191025 Pledgee: Wuhan Jiangxia sub branch of Bank of Communications Co., Ltd Pledgor: QR PHARMACEUTICALS Ltd. Registration number: Y2020980003662 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |